Zheng Ming-Hua, Meng Mao-Bin, Gu Dian-Na, Zhang Lei, Wu Ai-Min, Jiang Qian, Chen Yong-Ping
Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
Division of Thoracic Oncology, Cancer Center, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Curr Ther Res Clin Exp. 2009 Aug;70(4):323-34. doi: 10.1016/j.curtheres.2009.08.001.
Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). The beneficial effects of pharmaco-logic treatment of acute pancreatitis are unclear. Although the prophylactic use of NSAIDs for the reduction of the risk for pancreatic injury after ERCP has been assessed, the beneficial effects of NSAIDs on pancreatic injury are still being debated.
The aim of this study was to determine the effectiveness and tolerability of NSAIDs in the prophylaxis of post-ERCP pancreatitis (PEP).
MEDLINE (January 1966-January 2009), EMBASE (January 1966-January 2009), and the Cochrane Central Register of Controlled Trials (Issue 1, 2009) were searched using the key terms: pancreatitis, post-ERCP pancreatitis, nonsteroidal anti-inflammatory drugs, indomethacin, and diclofenac. The methods recommended by the Cochrane Collaboration and the Quality of Reporting Meta-Analyses guideline were used to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) of NSAIDs in the prevention of PEP.
Four multinational RCTs were included in the meta-analysis (969 patients). The pooled odds ratio for NSAIDs for mild PEP was 0.69 (95% CI, 0.40-1.17; P = NS); moderate to severe PEP, 0.22 (95% CI, 0.05-1.01; P = 0.05); PEP (pooled), 0.44 (95% CI, 0.21-0.93; P = 0.03); in high-risk patients, 0.49 (95% CI, 0.17-1.39; P = NS); and in low-risk patients, 0.29 (95% CI, 0.12-0.71; P = 0.006). No evidence of publication bias was found.
Based on the findings from the present systematic review of 4 RCTs, NSAIDs were effective and well tolerated in the prevention of PEP, especially in low-risk patients.
急性胰腺炎是内镜逆行胰胆管造影术(ERCP)的常见并发症。药物治疗急性胰腺炎的有益效果尚不清楚。尽管已经评估了预防性使用非甾体抗炎药(NSAIDs)以降低ERCP后胰腺损伤风险的效果,但NSAIDs对胰腺损伤的有益效果仍存在争议。
本研究旨在确定NSAIDs预防ERCP术后胰腺炎(PEP)的有效性和耐受性。
使用关键词“胰腺炎”“ERCP术后胰腺炎”“非甾体抗炎药”“吲哚美辛”和“双氯芬酸”检索MEDLINE(1966年1月至2009年1月)、EMBASE(1966年1月至2009年1月)以及Cochrane对照试验中央注册库(2009年第1期)。采用Cochrane协作网推荐的方法和报告元分析质量指南,对NSAIDs预防PEP的随机对照试验(RCTs)进行系统评价和元分析。
元分析纳入了4项多国RCTs(969例患者)。NSAIDs预防轻度PEP的合并比值比为0.69(95%可信区间,0.40 - 1.17;P = 无统计学意义);预防中度至重度PEP的合并比值比为0.22(95%可信区间,0.05 - 1.01;P = 0.05);预防PEP(合并)的合并比值比为0.44(95%可信区间,0.21 - 0.93;P = 0.03);在高危患者中,合并比值比为0.49(95%可信区间,0.17 - 1.39;P = 无统计学意义);在低危患者中,合并比值比为0.29(95%可信区间,0.12 - 0.71;P = 0.006)。未发现发表偏倚的证据。
基于对4项RCTs的本系统评价结果,NSAIDs在预防PEP方面有效且耐受性良好,尤其是在低危患者中。